All News

RheumNow Podcast square

Best Rheumatologists (7.19.2024)

Jack Cush, MD

This week on the RheumNow Podcast, Dr. Jack Cush reviews the news and journal reports of interesting, including irAE, pollution and Psoriasis, microwave therapy, scleroderma without scleroderma that only the best rheumatologists could discern.

Read Article
RheumNow Podcast square

Pollution and Autoimmunity (7.12.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article
PMR spotlight

PMR - a Risk Factor for Recalcitrant Giant Cell Arteritis?

Jack Cush, MD

Despite the clinical similarities and treatment differences between  giant cell arteritis (GCA polymyalgia rheumatica (PMR), confusion exists regarding the impact of overlapping disorders.

Read Article
FDG,PET,CT

ICYMI: Best Imaging in Giant Cell Arteritis - US, PET, MRI?

Jack Cush, MD

Imaging is often instrumental in diagnosing and staging patients diagnosed with giant cell arteritis. A new study compared the diagnostic performance of Colour Duplex Ultrasound (CDUS), Fluor-18-deoxyglucose Positron Emission Tomography Computed Tomography and Magnetic Resonance Imaging in patients suspected of giant cell arteritis and found the CDUS had a numerically higher sensitivity (that was not statistically superior to other modalities).

Read Article
GCA,woman

JAK Inhibitors in Giant Cell Arteritis

Jack Cush, MD

Trials are underway evaluating the potential benefits of JAK inhibitors (JAKi) in giant cell arteritis (GCA) patients who are refractory to standards of care.

Read Article
JAK Janus

New indications for JAK inhibitors

Janet Pope, MD, MPH, FRCPC

There are several new positive RCTs for JAK inhibitors. Here is a summary of trials and new indications for JAKi in GCA, pediatrics, GI, dermatology and more.

Read Article
EULAR24,Roundup

EULAR 2024 Rheumatology Roundup (6.21.2024)

Jack Cush, MD

Drs. Artie Kavanaugh and Jack Cush discuss highlights from the EULAR 2024 meeting in Vienna

Read Article
Convention1.jpg

EULAR 2024 – Day 4 Report

Jack Cush, MD

The final day of EULAR 2024 was rich in posters, Late-breaking oral presentations and EULAR updates and recommendations.  Below is a synopsis of the half-day's action.

Read Article
From LG cohort of myeloid neoplasms (861 MDS, 640 AML, 112 MDS/MPN, 89 MPN) autoimmune Rheum Dz (AIRD) found in 7.7% (lit suggests 8-30%), less in AML (4.7% vs 9.5% others). Common: RA (42%), CTD(18%), PMR (14%), vasculitis (12%), AxSpA (7%). https://t.co/ZXxOrZBunZ https://t.co/m5nIgrhohw

Links:

Dr. John Cush RheumNow ( View Tweet)
AbbVie has submitted regulatory applications to both the FDA and the European Medicines Agency for Rinvoq (upadacitinib) to treat adult patients with giant cell arteritis (GCA) https://t.co/LqRcm2FEFV https://t.co/XEjjSNnOGt

Links:

Dr. John Cush RheumNow ( View Tweet)
PMR - a Risk Factor for Recalcitrant Giant Cell Arteritis? Despite the clinical similarities and treatment differences between giant cell arteritis (GCA polymyalgia rheumatica (PMR), confusion exists regarding the impact of overlapping disorders. https://t.co/Slnq68YQgh https://t.co/nCYswGmlCk

Links:

Dr. John Cush RheumNow ( View Tweet)
CT angio in 75 pts w/ Takayasu arteritis (40 w/ cDMARDs, 35 biologics) showed reduced arterial thickness in 73% (31% w/ >25% decr in wall thickness). 1st immunosuppressives (p= 0.012) & bDMARDs(p= 0.026) reduced art. wall thickness (relative to cDMARDs) https://t.co/16eGmgVoWr https://t.co/AyNyT7FsYZ

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Best Imaging in Giant Cell Arteritis - US, PET, MRI? https://t.co/J4aE4jxNb0 https://t.co/b6axwp4Tuw

Links:

Dr. John Cush RheumNow ( View Tweet)
RT @drdavidliew I have to say: upadacitinib looks very decent for GCA. Not a panacea, but it definitely does something & good safety during trial. Would love to eventually see: - H2H comparative effect vs toci, secukinumab - structural outcomes - long-term safety #EULAR2024

Dr. John Cush RheumNow ( View Tweet)

JAK Inhibitors in GCA Trials are underway evaluating the potential benefits of JAKi in GCA patients who are refractory to standards of care. An observational real-world analysis of a small worldwide cohort suggests the utility of JAKi in GCA. https://t.co/d4IsqBgkxQ https://t.co/PIDhwzgNym

Links:

Dr. John Cush RheumNow ( View Tweet)
Select your GCA Therapy Dr. David Liew discusses LBA0001 presented at Eular 2024 in Vienna, Austria. https://t.co/TPBeU7KaEq https://t.co/09uEzM3Kkd

Links:

Dr. John Cush RheumNow ( View Tweet)
Giant Cell Arteritis and Polymyalgia Rheumatica Update Dr. Janet Pope discusses abstracts LBA0001, OP0233, OP0261 and POS0280 at Eular 2024 in Vienna, Austria. https://t.co/0V9Sle0GMU https://t.co/ixeT8L562C

Links:

Dr. John Cush RheumNow ( View Tweet)
Choices in GCA https://t.co/e994wGiUwb https://t.co/psr9NV0OA6

Links:

Dr. John Cush RheumNow ( View Tweet)
#POS0234 The effect of prophylactic Septrin in ANCA #vasculitis pts treated with RTX/CyC need further characterisation. Multicentre study in Korea showed protective effect on Serious Infection btw those treated vs not. Effect was seen in the 1st 3mths only #EULAR2024 @Yuz6Yusof https://t.co/tOOvvVynKA
Dr. John Cush RheumNow ( View Tweet)
RCT of #upadacitinib in #GCA It works to steroid spare 15 mg > 7.5 mg in outcomes Both >>placebo Ethically PBO had slower #prednisone taper Similar to #TCZ data What to choose in GCA IL6i? IL17i? JAKi? @eular_org # LBA0001 @Janetbirdope https://t.co/DGOltriVYF
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×